These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 24115329)
21. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. Marks RM; Ryan A; Heba ER; Tang A; Wolfson TJ; Gamst AC; Sirlin CB; Bashir MR AJR Am J Roentgenol; 2015 Mar; 204(3):527-35. PubMed ID: 25714281 [TBL] [Abstract][Full Text] [Related]
22. The combination of hepatobiliary phase with Gd-EOB-DTPA and DWI is highly accurate for the detection and characterization of liver metastases from neuroendocrine tumor. Hayoz R; Vietti-Violi N; Duran R; Knebel JF; Ledoux JB; Dromain C Eur Radiol; 2020 Dec; 30(12):6593-6602. PubMed ID: 32601948 [TBL] [Abstract][Full Text] [Related]
23. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759 [TBL] [Abstract][Full Text] [Related]
24. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216 [TBL] [Abstract][Full Text] [Related]
25. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. Kim JE; Kim SH; Lee SJ; Rhim H AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265 [TBL] [Abstract][Full Text] [Related]
26. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092 [TBL] [Abstract][Full Text] [Related]
27. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319 [TBL] [Abstract][Full Text] [Related]
28. Value of gadoxetic acid-enhanced and diffusion-weighted MR imaging in evaluation of hepatocellular carcinomas with atypical enhancement pattern on contrast-enhanced multiphasic MDCT in patients with chronic liver disease. Kim HS; Kim SH; Kang TW; Song KD; Choi D; Park CK Eur J Radiol; 2015 Apr; 84(4):555-62. PubMed ID: 25617950 [TBL] [Abstract][Full Text] [Related]
29. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677 [TBL] [Abstract][Full Text] [Related]
30. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging? Park SH; Kim B; Kim SY; Choi SJ; Huh J; Kim HJ; Kim KW; Lee SS Korean J Radiol; 2020 Mar; 21(3):280-289. PubMed ID: 32090520 [TBL] [Abstract][Full Text] [Related]
31. Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation. Böttcher J; Hansch A; Pfeil A; Schmidt P; Malich A; Schneeweiss A; Maurer MH; Streitparth F; Teichgräber UK; Renz DM Eur J Radiol; 2013 Nov; 82(11):1860-9. PubMed ID: 23932636 [TBL] [Abstract][Full Text] [Related]
32. Diffusion weighted imaging of liver lesions suspect for metastases: Apparent diffusion coefficient (ADC) values and lesion contrast are independent from Gd-EOB-DTPA administration. Benndorf M; Schelhorn J; Dietzel M; Kaiser WA; Baltzer PA Eur J Radiol; 2012 Aug; 81(8):e849-53. PubMed ID: 22575171 [TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609 [TBL] [Abstract][Full Text] [Related]
34. Diffusion-weighted imaging of the liver in patients with chronic liver disease: comparison of monopolar and bipolar diffusion gradients for image quality and lesion detection. Lewis S; Kamath A; Chatterji M; Patel A; Shyknevsky I; Dyvorne HA; Kuehn B; Taouli B AJR Am J Roentgenol; 2015 Jan; 204(1):59-68. PubMed ID: 25539238 [TBL] [Abstract][Full Text] [Related]
35. Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis. Li X; Li C; Wang R; Ren J; Yang J; Zhang Y PLoS One; 2015; 10(12):e0144247. PubMed ID: 26629904 [TBL] [Abstract][Full Text] [Related]
36. Hypervascular hepatocellular carcinoma in the cirrhotic liver: diffusion-weighted imaging versus superparamagnetic iron oxide-enhanced MRI. Chung J; Yu JS; Kim DJ; Chung JJ; Kim JH; Kim KW Magn Reson Imaging; 2011 Nov; 29(9):1235-43. PubMed ID: 21907517 [TBL] [Abstract][Full Text] [Related]
37. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study. Kim SS; Kim SH; Song KD; Choi SY; Heo NH J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483 [TBL] [Abstract][Full Text] [Related]
38. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994 [TBL] [Abstract][Full Text] [Related]
39. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. Haradome H; Grazioli L; Tinti R; Morone M; Motosugi U; Sano K; Ichikawa T; Kwee TC; Colagrande S J Magn Reson Imaging; 2011 Jul; 34(1):69-78. PubMed ID: 21598343 [TBL] [Abstract][Full Text] [Related]
40. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard. Hardie AD; Kizziah MK; Rissing MS J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]